Understanding GLP-1 Drugs and Their Impact
The CLVG virtual meeting, held on April 24, 2025, was facilitated by Roy Strasburger , CEO of StrasGlobal, president of Compliance Safe, and Vision Group Network co-founder. He set the stage by emphasizing how GLP-1 drugs, originally developed for diabetes but now widely used for weight loss, represent a potentially transformative shift in consumer purchasing patterns. The featured presenter, Sherry Frey , vice president of Total
Wellness at Nielsen IQ (NIQ), delivered a comprehensive analysis of GLP-1 drugs’ current market penetration, projected growth, and implications for convenience retailers in her presentation, “Understanding GLP-1 and Wellness Shifts Impacting C-stores.” Frey was joined by her colleague James Hunt , senior vice president - North American Retail from NIQ, who provided additional insights specific to the convenience channel.
The significance of GLP-1 drugs stems from their ability to target a deeply motivating factor for consum- ers: the desire to lose weight and feel better without significant lifestyle changes. Unlike other health trends that come and go, this fundamental motivation might make the impact of these drugs more enduring in the marketplace. In her presentation, Frey offered a very detailed explanation of GLP-1s, including how they work, who is using them, and future product development, as well as side effects that are and will have a major impact on shopper behavior.
“ The GLP-1s are a big piece, but they are just a piece, of a catalyzing moment that we have right now, especially in the U.S., around how people are thinking about what they’re eating and how they’re looking at that.
Sherry Frey , Vice President of Total Wellness, Nielsen IQ
© 2025 Vision Group Network LLC
www.vgnsharing.com
Powered by FlippingBook